Survodutide for Weight Loss and Blood Sugar: What a Meta-Analysis of 3 Clinical Trials Found
Survodutide, a dual GLP-1/glucagon receptor agonist, produced significant weight loss (~7.8%) and blood sugar improvements but with nearly triple the rate of side effects versus placebo.
Quick Facts
What This Study Found
This systematic review and meta-analysis pooled data from 3 randomized controlled trials involving 1,088 patients with diabetes and/or obesity. Survodutide at 2.4 mg/week produced a mean body weight reduction of 7.79% compared to placebo. HbA1c also decreased significantly.
However, the 2.4 mg dose was associated with nearly 3 times the odds of treatment-emergent adverse events (OR 2.93) compared to placebo, though severe adverse events were not increased. Gastrointestinal side effects were the most common and were dose-dependent. Treatment discontinuation due to side effects was also significantly higher with survodutide and increased with dose. The authors concluded that the optimal dose range appears to be 2.4 to 4.8 mg/week.
Key Numbers
n=1,088 across 3 RCTs · -7.79% body weight at 2.4 mg · OR 2.93 for adverse events vs placebo · Follow-up: 4–11 months · Optimal range: 2.4–4.8 mg/week
How They Did This
Systematic review and meta-analysis of randomized controlled trials from electronic databases. Included studies involved patients with diabetes and/or obesity receiving once-weekly subcutaneous survodutide versus placebo or active comparator. Primary outcomes were percent changes in body weight and HbA1c. Secondary outcomes included absolute weight change, blood pressure, fatty liver parameters, and adverse events.
Why This Research Matters
Survodutide is part of the next wave of multi-agonist weight loss peptides that target both the GLP-1 and glucagon receptors simultaneously. This meta-analysis is one of the first to pool clinical trial data for survodutide, providing a clearer picture of its efficacy-safety balance. The impressive weight loss comes with a meaningful side effect burden, which will be critical to manage as the drug moves through development.
The Bigger Picture
The metabolic drug pipeline is increasingly focused on multi-receptor agonists. Tirzepatide targets GLP-1 and GIP; survodutide targets GLP-1 and glucagon. The glucagon component may offer additional benefits for fatty liver disease and energy expenditure, but also introduces unique side effects. This meta-analysis positions survodutide as a potent but not yet fully characterized contender in the weight loss peptide space.
What This Study Doesn't Tell Us
Only 3 RCTs were available for analysis, with follow-up ranging from just 4 to 11 months — too short to assess long-term safety or weight maintenance. There was high statistical heterogeneity (I² = 98% for weight loss), suggesting the included trials had meaningfully different results. Long-term cardiovascular outcome data and head-to-head comparisons with established GLP-1 drugs are lacking.
Questions This Raises
- ?How does survodutide's weight loss compare head-to-head with tirzepatide or high-dose semaglutide?
- ?Will the glucagon receptor component provide meaningful benefits for fatty liver disease beyond what GLP-1 alone achieves?
- ?Can the high discontinuation rate be managed with slower dose titration or supportive medications?
Trust & Context
- Key Stat:
- -7.79% body weight Mean weight reduction with survodutide 2.4 mg/week versus placebo across 3 pooled clinical trials, achieved over 4 to 11 months of treatment.
- Evidence Grade:
- This is a systematic review and meta-analysis of RCTs, which is generally the highest level of evidence. However, only 3 trials were available, heterogeneity was very high, and follow-up was short, placing this at moderate rather than strong evidence.
- Study Age:
- Published in 2025. This is current and represents the most recent pooled analysis of survodutide clinical trial data available.
- Original Title:
- Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis.
- Published In:
- Indian journal of endocrinology and metabolism, 29(3), 253-259 (2025)
- Authors:
- Dutta, Deep(10), Kamrul-Hasan, Abul B M, Joshi, Ameya(3), Dhall, Anil, Nagendra, Lakshmi, Sharma, Meha
- Database ID:
- RPEP-10794
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
How is survodutide different from semaglutide (Ozempic/Wegovy)?
Semaglutide activates only the GLP-1 receptor, while survodutide activates both GLP-1 and glucagon receptors. The glucagon component may boost energy expenditure and offer additional benefits for fatty liver disease, but it also comes with a different side effect profile. Survodutide is based on the natural hormone oxyntomodulin, which activates both receptors.
Is survodutide available now?
No. Survodutide is still in clinical trials and has not been approved by the FDA or other regulatory agencies. This meta-analysis pooled early clinical trial data to evaluate its efficacy and safety profile as it moves through development.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-10794APA
Dutta, Deep; Kamrul-Hasan, Abul B M; Joshi, Ameya; Dhall, Anil; Nagendra, Lakshmi; Sharma, Meha. (2025). Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis.. Indian journal of endocrinology and metabolism, 29(3), 253-259. https://doi.org/10.4103/ijem.ijem_366_24
MLA
Dutta, Deep, et al. "Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis.." Indian journal of endocrinology and metabolism, 2025. https://doi.org/10.4103/ijem.ijem_366_24
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and Safety of Twincretin Survodutide, a Dual Glucag..." RPEP-10794. Retrieved from https://rethinkpeptides.com/research/dutta-2025-efficacy-and-safety-of-2
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.